Subscribe To
Chemocentryx, allogene show the risks and rewards of nasdaq biotech stocks
The broader market was mixed on Friday....
October 8, 2021, 1:10 pm
Why allogene therapeutics stock is getting hammered today
A possible safety issue is crushing the biotech's shares today....
October 8, 2021, 12:57 pm
Why allogene therapeutics stock is getting hammered today
A possible safety issue is crushing the biotech's shares today....
October 8, 2021, 12:57 pm
Why allogene therapeutics stock is getting hammered today
A possible safety issue is crushing the biotech's shares today....
October 8, 2021, 12:57 pm
biotech stock hits record lows on fda hold
Allogene Therapeutics Inc (NASDAQ:ALLO) is plummeting this morning, down 42% to trade at $14.13 at last check, one of the worst stock's on the Nasdaq ...
October 8, 2021, 10:52 am
biotech stock hits record lows on fda hold
Allogene Therapeutics Inc (NASDAQ:ALLO) is plummeting this morning, down 42% to trade at $14.13 at last check, one of the worst stock's on the Nasdaq ...
October 8, 2021, 10:52 am
biotech stock hits record lows on fda hold
Allogene Therapeutics Inc (NASDAQ:ALLO) is plummeting this morning, down 42% to trade at $14.13 at last check, one of the worst stock's on the Nasdaq ...
October 8, 2021, 10:52 am
Cidara therapeutics announces pricing of concurrent public offerings of common stock and preferred stock
SAN DIEGO, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics des...
October 8, 2021, 9:12 am
Cidara therapeutics announces pricing of concurrent public offerings of common stock and preferred stock
SAN DIEGO, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics des...
October 8, 2021, 9:12 am
Cidara therapeutics announces pricing of concurrent public offerings of common stock and preferred stock
SAN DIEGO, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics des...
October 8, 2021, 9:12 am
Isoplexis ipo priced in the middle of expected range, as the biotech raised $125 million
IsoPlexis Corp. ISO, +0.36% is primed to go public Friday, after the Connecticut-based biotechnology company's initial public offering priced overnigh...
October 8, 2021, 6:22 am
Isoplexis ipo priced in the middle of expected range, as the biotech raised $125 million
IsoPlexis Corp. ISO, +0.36% is primed to go public Friday, after the Connecticut-based biotechnology company's initial public offering priced overnigh...
October 8, 2021, 6:22 am
Isoplexis ipo priced in the middle of expected range, as the biotech raised $125 million
IsoPlexis Corp. ISO, +0.36% is primed to go public Friday, after the Connecticut-based biotechnology company's initial public offering priced overnigh...
October 8, 2021, 6:22 am
Allogene therapeutics stock halted as fda puts hold on cancer drug study
Allogene Therapeutics Inc. ALLO, +1.71% shares were halted in the extended session Thursday after the biotech ...
October 7, 2021, 4:44 pm
Allogene therapeutics stock halted as fda puts hold on cancer drug study
Allogene Therapeutics Inc. ALLO, +1.71% shares were halted in the extended session Thursday after the biotech ...
October 7, 2021, 4:44 pm
Allogene therapeutics stock halted as fda puts hold on cancer drug study
Allogene Therapeutics Inc. ALLO, +1.71% shares were halted in the extended session Thursday after the biotech ...
October 7, 2021, 4:44 pm
Beigene announces first regulatory approval in australia for brukinsa® (zanubrutinib) for treatment of patients with waldenström's macroglobulinemia
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focus...
October 7, 2021, 4:06 pm
Beigene announces first regulatory approval in australia for brukinsa® (zanubrutinib) for treatment of patients with waldenström's macroglobulinemia
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focus...
October 7, 2021, 4:06 pm
Beigene announces first regulatory approval in australia for brukinsa® (zanubrutinib) for treatment of patients with waldenström's macroglobulinemia
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focus...
October 7, 2021, 4:06 pm
Trevi therapeutics participating in alliance global partners' virtual biotech & specialty pharma conference
NEW HAVEN, Conn., Oct. 7, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the dev...
October 7, 2021, 4:05 pm